Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942523 | 0.84 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL13942526 | 0.81 | RAB9A (0.45) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL9397355 | 0.81 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL13942528 | 0.79 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL4173129 | 0.77 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL13942532 | 0.77 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL11726417 | 0.76 | RAB9A (0.69) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL3984192 | 0.76 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL4161199 | 0.73 | ALDH1A1 (0.40) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 | |
| SCHEMBL13219331 | 0.72 | RAB9A (0.64) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| WO-2007014226-A2 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATION AND STROKE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014226-A2 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATION AND STROKE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | RAB9A 2534/4885SMN1; SMN2 89/4885NPC1 996/4885 |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | RAB9A 2534/4885SMN1; SMN2 89/4885NPC1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.